venetoclax Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5133 1257044-40-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • venclyxto
  • venetoclax
  • ABT-199
  • venclexta
  • GDC-0199
Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2.
  • Molecular weight: 868.45
  • Formula: C45H50ClN7O7S
  • CLOGP: 10.31
  • LIPINSKI: 3
  • HAC: 14
  • HDO: 3
  • TPSA: 172.03
  • ALOGS: -5.97
  • ROTB: 12

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 20, 2019 PMDA AbbVie GK
Dec. 5, 2016 EMA AbbVie Ltd
April 11, 2016 FDA ABBVIE INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 1018.66 52.11 320 882 81148 2275735
Intentional product use issue 720.77 52.11 135 1067 3467 2353416
Off label use 514.93 52.11 190 1012 73408 2283475
Acute myeloid leukaemia 357.70 52.11 72 1130 2638 2354245
Neutropenia 261.83 52.11 85 1117 21463 2335420
Chronic lymphocytic leukaemia 196.72 52.11 34 1168 521 2356362
Febrile neutropenia 139.95 52.11 45 1157 10837 2346046
Tumour lysis syndrome 126.22 52.11 26 1176 1049 2355834
Disease progression 120.05 52.11 45 1157 17050 2339833
Sepsis 116.62 52.11 45 1157 18443 2338440
Platelet count decreased 112.36 52.11 42 1160 15771 2341112
Hospice care 107.59 52.11 21 1181 641 2356242
Richter's syndrome 106.55 52.11 15 1187 50 2356833
Pyrexia 102.71 52.11 57 1145 53651 2303232
White blood cell count decreased 92.70 52.11 38 1164 18170 2338713
Infection 82.90 52.11 35 1167 17994 2338889
Thrombocytopenia 71.17 52.11 32 1170 19099 2337784
Pneumonia 69.42 52.11 43 1159 49253 2307630
Pancytopenia 65.43 52.11 26 1176 11426 2345457
Hospitalisation 58.90 52.11 26 1176 14827 2342056
Lymphadenopathy 58.78 52.11 20 1182 5678 2351205
Haemoglobin decreased 53.91 52.11 26 1176 18125 2338758

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 1307.44 44.64 511 1516 86932 1657822
Intentional product use issue 1069.03 44.64 212 1815 2507 1742247
Off label use 777.05 44.64 285 1742 38286 1706468
Acute myeloid leukaemia 451.82 44.64 107 1920 2934 1741820
Chronic lymphocytic leukaemia 419.49 44.64 81 1946 795 1743959
Neutropenia 301.38 44.64 118 1909 18142 1726612
Tumour lysis syndrome 298.48 44.64 69 1958 1682 1743072
Febrile neutropenia 241.64 44.64 88 1939 11012 1733742
Platelet count decreased 200.98 44.64 86 1941 16437 1728317
Richter's syndrome 174.01 44.64 29 1998 107 1744647
Pneumonia 168.76 44.64 107 1920 46075 1698679
Hospice care 165.37 44.64 35 1992 555 1744199
Disease progression 165.21 44.64 76 1951 17187 1727567
Pyrexia 141.25 44.64 96 1931 46304 1698450
White blood cell count decreased 135.45 44.64 61 1966 13088 1731666
Infection 126.19 44.64 57 1970 12303 1732451
Lymphadenopathy 121.30 44.64 41 1986 4073 1740681
Sepsis 118.44 44.64 63 1964 19375 1725379
Asthenia 117.96 44.64 77 1950 34593 1710161
Haemoglobin decreased 105.70 44.64 56 1971 17058 1727696
Pancytopenia 86.97 44.64 43 1984 11314 1733440
Blood count abnormal 82.78 44.64 24 2003 1433 1743321
General physical health deterioration 81.11 44.64 43 1984 13075 1731679
Thrombocytopenia 73.99 44.64 48 1979 21201 1723553
Hospitalisation 68.38 44.64 38 1989 12662 1732092
Fatigue 67.69 44.64 65 1962 50716 1694038
Diarrhoea 64.46 44.64 65 1962 53787 1690967
Cytopenia 55.74 44.64 16 2011 920 1743834
Septic shock 54.10 44.64 28 1999 8081 1736673
Acute myeloid leukaemia recurrent 53.18 44.64 12 2015 258 1744496
Atrial fibrillation 52.19 44.64 34 1993 15077 1729677
Anaemia 51.50 44.64 44 1983 29413 1715341
Splenomegaly 46.58 44.64 17 2010 2103 1742651
Mantle cell lymphoma 45.50 44.64 11 2016 322 1744432

Pharmacologic Action:

SourceCodeDescription
ATC L01XX52 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
CHEBI has role CHEBI:35610 antineoplastic agent
FDA EPC N0000192515 BCL-2 Inhibitor
FDA PE N0000009176 Increased Cellular Death
FDA MoA N0000185503 P-Glycoprotein Inhibitors
MeSH PA D000970 Antineoplastic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic lymphoid leukemia, disease indication 92814006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.0 acidic
pKa2 13.01 acidic
pKa3 7.73 Basic
pKa4 4.24 Basic
pKa5 3.47 Basic
pKa6 0.56 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9174982 May 26, 2030 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9539251 Sept. 6, 2033 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9539251 Sept. 6, 2033 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL 9539251 Sept. 6, 2033 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2021 NEW CHEMICAL ENTITY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2021 NEW CHEMICAL ENTITY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2021 NEW CHEMICAL ENTITY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2021 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2021 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2021 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2021 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2022 VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2022 VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2022 VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2023 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2023 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL April 11, 2023 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2025 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2025 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL June 8, 2025 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2025 INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2025 INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL Nov. 21, 2025 INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
100MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2026 TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
10MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2026 TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
50MG VENCLEXTA ABBVIE INC N208573 April 11, 2016 RX TABLET ORAL May 15, 2026 TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Apoptosis regulator Bcl-2 Cytosolic other INHIBITOR Ki 11 SCIENTIFIC LITERATURE DRUG LABEL
Bcl-2-like protein 1 Cytosolic other INHIBITOR Ki 7.32 SCIENTIFIC LITERATURE
Apoptosis regulator Bcl-W Cytosolic other INHIBITOR Ki 6.61 SCIENTIFIC LITERATURE

External reference:

IDSource
D10679 KEGG_DRUG
763511000 SNOMEDCT_US
1747556 RXNORM
016803 NDDF
4035629 VANDF
31601 MMSL
d08429 MMSL
720491001 SNOMEDCT_US
49846579 PUBCHEM_CID
CHEBI:133021 CHEBI
N54AIC43PW UNII
9925 INN_ID
DB11581 DRUGBANK_ID
CHEMBL3137309 ChEMBL_ID
8318 IUPHAR_LIGAND_ID
C579720 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Venclexta HUMAN PRESCRIPTION DRUG LABEL 1 0074-0561 TABLET, FILM COATED 10 mg ORAL NDA 18 sections
Venclexta HUMAN PRESCRIPTION DRUG LABEL 1 0074-0566 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Venclexta HUMAN PRESCRIPTION DRUG LABEL 1 0074-0576 TABLET, FILM COATED 100 mg ORAL NDA 18 sections
Venclexta HUMAN PRESCRIPTION DRUG LABEL 4 0074-0579 KIT 50 mg None NDA 18 sections
Venclexta HUMAN PRESCRIPTION DRUG LABEL 4 0074-0579 KIT 100 mg None NDA 18 sections
Venclexta HUMAN PRESCRIPTION DRUG LABEL 4 0074-0579 KIT 10 mg None NDA 18 sections
Venclexta HUMAN PRESCRIPTION DRUG LABEL 4 0074-0579 KIT 100 mg None NDA 18 sections